| 0.9055 -0.02 (-2.11%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.17  |
1-year : | 1.3 |
| Resists | First : | 1 |
Second : | 1.12 |
| Pivot price | 0.99 |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 0.96 |
| MA(100) : | 1.05 |
MA(250) : | 0.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 30.2 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 1.45 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEON ] has closed above bottom band by 15.7%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.97 | 0.97 - 0.97 |
| Low: | 0.89 - 0.9 | 0.9 - 0.9 |
| Close: | 0.89 - 0.9 | 0.9 - 0.92 |
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Wed, 29 Apr 2026
AEON Biopharma (AEON) details 2026 meeting, director elections and KPMG ratification - Stock Titan
Fri, 24 Apr 2026
AEON Biopharma Sets Annual Shareholder Meeting - The Globe and Mail
Fri, 24 Apr 2026
AEON cites going concern audit note, cash into Q3 2026 - Stock Titan
Fri, 03 Apr 2026
AEON stays on NYSE despite $55 million deficit as deadline nears - Stock Titan
Fri, 03 Apr 2026
AEON Biopharma Received Notice of Noncompliance - TradingView
Thu, 26 Mar 2026
Aeon Biopharma announces FDA feedback after Type 2a meeting - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|